Patents Assigned to MedImmune, LLC
  • MULTI PLASMID SYSTEM FOR THE PRODUCTION OF INFLUENZA VIRUS
    Publication number: 20140220075
    Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided.
    Type: Application
    Filed: March 21, 2014
    Publication date: August 7, 2014
    Applicant: MEDIMMUNE, LLC
    Inventors: Enrich HOFFMAN, Hong Jin, Bin Lu, Greg Duke, George Kemble
  • Molecules with extended half-lives, compositions and uses thereof
    Patent number: 8795661
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: August 5, 2014
    Assignees: MedImmune, LLC, Board of Regents, The University of Texas System
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
  • TARGETED BINDING AGENTS DIRECTED TO DLL4 AND USES THEREOF
    Publication number: 20140206853
    Abstract: The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL4 and as diagnostics.
    Type: Application
    Filed: January 30, 2014
    Publication date: July 24, 2014
    Applicant: MedImmune, LLC
    Inventors: Ian Foltz, David Jenkins, Vahe Bedian
  • Methods for purification of viruses
    Patent number: 8785173
    Abstract: The present invention provides methods for the purification of cell-associated viruses from adherent cells (e.g., MDCK or Vero cells). In particular, the present invention provides purification methods for the production of immunogenic compositions comprising a live attenuated cell-associated virus (e.g., an attenuated respiratory syncytial virus (RSV) or cold-adapted, and/or temperature sensitive influenza virus) that result in levels of host cell DNA (HCD), host cell protein (HCP) and non-specific endonuclease (e.g., Benzonase), which are below the specifications required by regulatory agencies. The immunogenic compositions can be used to actively immunize subjects or to generate antibodies for a variety of uses, including passive immunization and diagnostic immunoassays.
    Type: Grant
    Filed: September 24, 2009
    Date of Patent: July 22, 2014
    Assignee: MedImmune, LLC
    Inventors: Mark Thompson, Janice Wee, Akanksha Nagpal
  • INFLUENZA B VIRUSES HAVING ALTERATIONS IN THE HEMAGLUTININ POLYPEPTIDE
    Publication number: 20140199683
    Abstract: The present invention encompasses methods of producing influenza B viruses in cell culture. The influenza B viruses may have desirable characteristics, such as enhanced replication in eggs and may be used, for example, in vaccines and in methods of treatment to protect against influenza B virus infection.
    Type: Application
    Filed: January 22, 2014
    Publication date: July 17, 2014
    Applicant: MEDIMMUNE, LLC
    Inventors: Hong JIN, Zhongying CHEN
  • Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
    Patent number: 8775090
    Abstract: Provided herein are crystalline forms of a human IgG Fc variant comprising triple-mutation M252Y/S254T/T256E that provides for increased binding affinity to human neonatal Fc receptor, methods of obtaining such crystals and high-resolution X-ray diffraction structures and atomic structure coordinates. Also provided are machine readable media embedded with the three-dimensional atomic structure coordinates of the human IgG Fc variant and methods of using them.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: July 8, 2014
    Assignee: MedImmune, LLC
    Inventors: Vaheh Oganesyan, William F. Dall'Acqua, Herren Wu
  • Influenza hemagglutinin and neuraminidase variants
    Patent number: 8765136
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: July 1, 2014
    Assignee: MedImmune, LLC
    Inventors: Chin-Fen Yang, George Kemble, Kanta Subbarao, Brian Murphy
  • Modulation Of Antibody Effector Function By Hinge Domain Engineering
    Publication number: 20140171623
    Abstract: The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., Fc?Rs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc?R and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
    Type: Application
    Filed: February 17, 2014
    Publication date: June 19, 2014
    Applicant: MedImmune, LLC
    Inventors: William Dall'Acqua, Herren Wu, Melissa Damschroder, Jose Casas-Finet
  • Molecules With Extended Half-Lives And Uses Thereof
    Publication number: 20140170142
    Abstract: The invention is directed to a molecule comprising an albumin binding domain (ABD) and an FcRn binding moiety, wherein said molecule has enhanced pharmacologic properties in vivo.
    Type: Application
    Filed: January 13, 2014
    Publication date: June 19, 2014
    Applicant: MEDIMMUNE, LLC
    Inventors: OLGA LUBMAN, WILLIAM DALL'ACQUA, HERREN WU
  • Antibody formulations
    Patent number: 8754195
    Abstract: The present invention relates to formulations comprising sucrose, and methods of making such formulations, wherein the sucrose content promotes the reduction or elimination of the reversible self-association (RSA) tendency of the antibody in the formulation. The present invention also relates to formulations comprising an anti-PDGFR-alpha antibody or antibody fragment. Such antibodies can be used in various methods of treatment. The application further relates to a method of eliminating or reducing the RSA tendency of antibodies in a formulation.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: June 17, 2014
    Assignee: MedImmune, LLC
    Inventors: Mariana N. Dimitrova, Neil Mody
  • Non-tumorigenic MDCK cell line for propagating viruses
    Patent number: 8748174
    Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: June 10, 2014
    Assignee: MedImmune, LLC
    Inventors: Richard Schwartz, John Michael Berry, Ajit Subramanian, Xiao Shi
  • Methods and compositions for expressing negative-sense viral RNA in canine cells
    Patent number: 8742089
    Abstract: The present invention provides novel canine pol I regulatory nucleic acid sequences useful for the expression of nucleic acid sequences in canine cells such as MDCK cells. The invention further provides expression vectors and cells comprising such nucleic acids as well as methods of using such nucleic acids to make influenza viruses, including infectious influenza viruses.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: June 3, 2014
    Assignee: MedImmune, LLC
    Inventors: Gregory Duke, George Kemble, James Young, Zhaoti Wang
  • HSA-Related Compositions And Methods Of Use
    Publication number: 20140148392
    Abstract: Provided are human serum albumin (HSA) compositions with improved properties over native HSA.
    Type: Application
    Filed: August 9, 2011
    Publication date: May 29, 2014
    Applicant: MEDIMMUNE, LLC
    Inventors: Changshou Gao, Chaity Chaudhury, Xiaotao Yao
  • Protein Scaffolds
    Publication number: 20140141994
    Abstract: The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds.
    Type: Application
    Filed: December 13, 2013
    Publication date: May 22, 2014
    Applicant: MedImmune, LLC
    Inventors: Herren Wu, Manuel Baca, Jeffrey Swers, Benoy Chacko
  • MULTI PLASMID SYSTEM FOR THE PRODUCTION OF INFLUENZA VIRUS
    Publication number: 20140134208
    Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. A method of producing a cold adapted (ca) influenza virus that replicates efficiently at, e.g., 25° C. (and immunogenic compositions comprising the same) is also provided.
    Type: Application
    Filed: September 26, 2013
    Publication date: May 15, 2014
    Applicant: MEDIMMUNE, LLC
    Inventors: Erich HOFFMANN, Hong JIN, George KEMBLE, Zhongying CHEN
  • Multi plasmid system for the production of influenza virus
    Patent number: 8722059
    Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: May 13, 2014
    Assignee: MedImmune, LLC
    Inventors: Erich Hoffman, Hong Jin, Bin Lu, Greg Duke, George Kemble
  • REFRIGERATOR-TEMPERATURE STABLE INFLUENZA VACCINE COMPOSITIONS
    Publication number: 20140127262
    Abstract: Methods and compositions for the optimization and production of refrigerator-temperature stable virus, e.g., influenza, compositions are provided. Formulations and immunogenic compositions comprising refrigerator-temperature stable virus compositions are provided.
    Type: Application
    Filed: January 8, 2014
    Publication date: May 8, 2014
    Applicant: MEDIMMUNE, LLC
    Inventors: George KEMBLE, George Robert TRAGER, Richard SCHWARTZ
  • Swine influenza hemagglutinin variants
    Patent number: 8715691
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: May 6, 2014
    Assignee: MedImmune, LLC
    Inventor: Hong Jin
  • Modulation of antibody effector function by hinge domain engineering
    Patent number: 8697396
    Abstract: The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., Fc?Rs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc?R and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: April 15, 2014
    Assignee: MedImmune, LLC
    Inventors: William Dall'Acqua, Herren Wu, Melissa Damschroder, Jose Casas-Finet
  • HSA-related compositions and methods of use
    Patent number: 8697650
    Abstract: Provided are human serum albumin (HSA) compositions with improved properties over native HSA.
    Type: Grant
    Filed: February 15, 2011
    Date of Patent: April 15, 2014
    Assignee: Medimmune, LLC
    Inventors: Changshou Gao, Chaity Chaudhury, Xiaotao Yao